Eye Infections Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/376x9w/eye_infections) has announced the addition of the "Eye Infections Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report provides an overview of Eye Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Eye Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Alcon - Allergan - Dompe Farmaceutici - InSite Vision - Laboratoires Thea - Merck & Co. - Novartis - SIFI - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/37...infections
AGN: 295.24 (+1.64), MRK: 52.09 (-0.63), VRX.TO: 298.92 (-3.40), NVS: 96.55 (+0.28)
Is Another Amendment of QLT-InSite Vision Deal Coming Up?
Zacks Equity Research - Zacks Investment Research - Tue Sep 08, 3:25PM CDT
InSite Vision Inc. (INSV), which is set to be acquired by QLT Inc. (QLTI), announced that it has received a superior unsolicited offer from a global pharmaceutical company.
QLTI: 3.44 (unch), GILD: 109.63 (+2.38), REGN: 533.30 (+2.08)
QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Sep 04, 8:01PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a "Company Superior Proposal"
Business Wire - Fri Sep 04, 4:49PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company (the "Bidder"
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Thu Sep 03, 5:35PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)
InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company
Business Wire - Thu Sep 03, 3:12PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite(TM) patent lawsuit. InSite Vision believes the lawsuit is without merit.
QLTI: 3.44 (unch)
InSite Vision Announces New Date for Special Stockholder Meeting
Business Wire - Wed Sep 02, 5:25PM CDT
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt a Second Amended and Restated Agreement and Plan of Merger, will now be held at 10:00 a.m. Pacific Time on October 9, 2015, for stockholders of record on September 8, 2015. InSite Vision had previously announced that the Special Meeting would be held on September 30, 2015. The Special Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015.
QLTI: 3.44 (unch)
InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit
Business Wire - Wed Sep 02, 3:05PM CDT
InSite Vision Inc. (OTCBB: INSV) today announced that Johnson Matthey Pharmaceutical Materials, Inc. (Johnson Matthey) has filed a patent lawsuit in the United States District Court for the District of Delaware in connection with activities relating to InSite Vision's New Drug Application (NDA) seeking commercial approval from the U.S. Food and Drug Administration (FDA) for BromSite(TM) (0.075% bromfenac) for the treatment of inflammation and prevention of pain associated with cataract surgery.
QLT Provides Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Aug 21, 7:39AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)
InSite Vision Determines that an Unsolicited Offer from a Multi-National Pharmaceutical Company to Acquire InSite for $0.25 in Cash Constitutes a "Company Superior Proposal"
Business Wire - Fri Aug 21, 7:30AM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors determined that the previously announced unsolicited offer from a multi-national pharmaceutical company (the "Bidder"
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)
Blepharitis Pipeline Review, H2 2015 - Reviews Key Players Involved in the Therapeutics Development for Blepharitis
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cb3rdq/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned - Allergan Plc - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. For more information visit http://www.researchandmarkets.com/research/cb...lepharitis
AGN: 295.24 (+1.64), FOMX: 9.95 (-0.04)
InSite Vision Announces FDA Acceptance of NDA Filing for BromSite(TM) (0.075% bromfenac)
Business Wire - Mon Aug 17, 3:05PM CDT
--Marketing approval is being sought for use in treatment of inflammation and prevention of pain after cataract surgery
InSite Vision falls to net loss of USD6.6m for Q2 2015
M2 - Wed Aug 12, 5:29AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) stated on Tuesday that it recorded a net loss of USD6.6m (USD0.05 per share) for the quarter ended 30 June 2015.
InSite Vision Announces Date for Special Stockholder Meeting
Business Wire - Tue Aug 11, 6:58PM CDT
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt an Agreement and Plan of Merger, will be held at 10:00 a.m. Pacific Time on September 30, 2015, for stockholders of record on August 25, 2015. The Special Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015.
QLTI: 3.44 (unch)
InSite Reports Second Quarter 2015 Financial Results
Business Wire - Tue Aug 11, 3:05PM CDT
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended June 30, 2015. Revenues for the quarter ended June 30, 2015 were $0.4 million compared to $6.3 million for the same period in 2014; revenues in 2014 included a $6.0 million payment from Akorn, Inc. for an amendment to their AzaSite(R) license agreement (Akorn License). Net loss for the quarter ended June 30, 2015 was $6.6 million, or $0.05 per share, compared to net income of $37.1 million, or $0.28 per share, in the second quarter of 2014. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes. As of June 30, 2015, cash and cash equivalents totaled $1.8 million.
QLTI: 3.44 (unch), AKRX: 38.38 (+0.33)
QLT Provides Update on Merger With InSite Vision Incorporated
GlobeNewswire - Mon Aug 10, 7:39AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)
InSite Vision Receives Unsolicited Proposal from a Multi-National Pharmaceutical Company
Business Wire - Mon Aug 10, 7:30AM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received an unsolicited proposal from a multi-national pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at a price of $0.25 per share in cash. The proposal is non-binding and is subject to further due diligence.
QLTI: 3.44 (unch)
Qiagen Inks Molecular Diagnostics Partnership with Seegene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 1:20PM CDT
Qiagen N.V. (QGEN) recently inked a worldwide collaboration agreement with multiplex molecular technologies and multiplex clinical molecular diagnostics developer Seegene Inc.
ACHN: 7.77 (+0.04), AMAG: 53.00 (-4.65), QGEN: 26.68 (+0.24)
Cataract - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d86sd5/cataract) has announced the addition of the "Cataract - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - CalAsia Pharmaceuticals, Inc. - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Laila Pharmaceuticals Pvt. Ltd. - Omeros Corporation - R-Tech Ueno, Ltd. For more information visit http://www.researchandmarkets.com/research/d86sd5/cataract
EYEG: 4.24 (-0.21), OMER: 14.12 (+0.33)
INSITE VISION INCORPORATED SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Wed Jun 17, 10:19AM CDT
Rigrodsky & Long, P.A.:
QLTI: 3.44 (unch)